Cancer Pain - Pipeline Review, H2 2013


#175353

145pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Cancer Pain Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cancer Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Pain. Cancer Pain Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Cancer Pain.
  • A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cancer Pain pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Cancer Pain.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Cancer Pain Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Cancer Pain 12
Cancer Pain Therapeutics under Development by Companies 14
Cancer Pain Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Cancer Pain Therapeutics - Products under Development by Companies 22
Cancer Pain Therapeutics - Products under Investigation by Universities/Institutes 24
Companies Involved in Cancer Pain Therapeutics Development 25
Kyowa Hakko Kirin Co., Ltd. 25
Amgen Inc. 26
BioDelivery Sciences International, Inc. 27
Daiichi Sankyo Company, Ltd 28
Sangamo BioSciences, Inc. 29
Egalet a/s 30
Alexza Pharmaceuticals, Inc. 31
Samyang Corporation 32
Aphios Corporation 33
AcelRx Pharmaceuticals, Inc. 34
Laboratoires Pierre Fabre SA 35
Nippon Kayaku Co., Ltd. 36
Nippon Shinyaku Co., Ltd. 37
Orion Corporation 38
Pfizer Inc. 39
Zeria Pharmaceutical Co Ltd 40
GW Pharmaceuticals plc 41
IntelGenx Technologies Corp. 42
Benitec Ltd. 43
NovaDel Pharma, Inc. 44
KOLON LIFE SCIENCE INC. 45
Diamyd Medical AB 46
BioAlliance Pharma SA 47
Labtec GmbH 48
Grunenthal GmbH 49
AngioChem Inc. 50
WEX Pharmaceuticals Inc. 51
QRxPharma Limited 52
APEIRON Biologics AG 53
Winston Pharmaceuticals, Inc. 54
Encore Therapeutics Inc. 55
Afferent Pharmaceuticals, Inc. 56
Cancer Pain - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Route of Administration 59
Assessment by Molecule Type 62
Drug Profiles 64
tanezumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
fentanyl - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
fentanyl - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
nabiximols - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
buprenorphine hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
dronabinol - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
fentanyl citrate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
fentanyl citrate - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Tetrodotoxin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ZFP Transcription Factors For Neuropathic Pain - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
(morphine + oxycodone) CR - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ARX-02 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
morphine sulfate ER - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
zucapsaicin - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
fulranumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
NP-2 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
ANG-2002 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
P2X3 Targeted Program - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
dexmedetomidine hydrochloride - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
tramadol hydrochloride SR - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
fentanyl - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Z-360 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
TK-641 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
THA-901 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
ddRNAi Program For Cancer-Associated Pain - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
APN-601 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
tapentadol ER - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
leconotide - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
hydromorphone - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
buprenorphine hydrochloride ER - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
AF-353 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
befiradol - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
NRT-12 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
DD-04107 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
QX-314 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
ifenprodil - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Calpastatin - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Drug For Pancreatic Cancer Pain - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
KLS-2010 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
XPG-110 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
PGN-202 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Cancer Pain Therapeutics - Drug Profile Updates 121
Cancer Pain Therapeutics - Discontinued Products 136
Cancer Pain Therapeutics - Dormant Products 137
Cancer Pain - Product Development Milestones 138
Featured News & Press Releases 138
Sep 03, 2013: Galena Biopharma Initiates RELIEF Patient Registry for Abstral Sublingual Tablets 138
Jul 31, 2013: Hisamitsu Pharmaceutical Submits Application Seeking Approval for Additional Indication of Chronic Pain for Fentos Tape, a Transdermal Long-Acting Cancer Pain Relief Patch 139
Jul 29, 2013: BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan 139
May 09, 2013: Galena Biopharma Presents Data On Development Of TIRF REMS Program At American Pain Society 32nd Annual Scientific Meeting 139
May 09, 2013: Purdue Pharma To Present Data Regarding Long-Term Opioid Therapy At APS Annual Meeting 140
Apr 05, 2013: Phosphagenics Receives Approval To Conduct Clinical Study Of Oxycodone Patch At Royal Adelaide Hospital 141
Apr 03, 2013: GW Pharma Receives US Patent Allowance For Delivery Of Sativex Formulation 141
Feb 14, 2013: US Federal Court Validates Cephalon’s Fentora Patents 142
Nov 13, 2012: Orexo Announces Submission Of New Drug Application For KW-2246 In Japan 142
Oct 15, 2012: BioDelivery Sciences Announces Launch Of Breakyl In EU 143

Appendix 144
Methodology 144
Coverage 144
Secondary Research 144
Primary Research 144
Expert Panel Validation 144
Contact Us 145
Disclaimer 145

Number of Products Under Development for Cancer Pain, H2 2013 12
Products under Development for Cancer Pain - Comparative Analysis, H2 2013 13
Number of Products under Development by Companies, H2 2013 15
Number of Products under Development by Companies, H2 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2013 17
Comparative Analysis by Late Stage Development, H2 2013 18
Comparative Analysis by Mid Clinical Stage Development, H2 2013 19
Comparative Analysis by Early Clinical Stage Development, H2 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 21
Products under Development by Companies, H2 2013 22
Products under Development by Companies, H2 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2013 24
Kyowa Hakko Kirin Co., Ltd., H2 2013 25
Amgen Inc., H2 2013 26
BioDelivery Sciences International, Inc., H2 2013 27
Daiichi Sankyo Company, Ltd, H2 2013 28
Sangamo BioSciences, Inc., H2 2013 29
Egalet a/s, H2 2013 30
Alexza Pharmaceuticals, Inc., H2 2013 31
Samyang Corporation, H2 2013 32
Aphios Corporation, H2 2013 33
AcelRx Pharmaceuticals, Inc., H2 2013 34
Laboratoires Pierre Fabre SA, H2 2013 35
Nippon Kayaku Co., Ltd., H2 2013 36
Nippon Shinyaku Co., Ltd., H2 2013 37
Orion Corporation, H2 2013 38
Pfizer Inc., H2 2013 39
Zeria Pharmaceutical Co Ltd, H2 2013 40
GW Pharmaceuticals plc, H2 2013 41
IntelGenx Technologies Corp., H2 2013 42
Benitec Ltd., H2 2013 43
NovaDel Pharma, Inc., H2 2013 44
KOLON LIFE SCIENCE INC., H2 2013 45
Diamyd Medical AB, H2 2013 46
Grunenthal GmbH, H2 2013 49
AngioChem Inc., H2 2013 50
WEX Pharmaceuticals Inc., H2 2013 51
QRxPharma Limited, H2 2013 52
APEIRON Biologics AG, H2 2013 53
Winston Pharmaceuticals, Inc., H2 2013 54
Encore Therapeutics Inc., H2 2013 55
Afferent Pharmaceuticals, Inc., H2 2013 56
Assessment by Monotherapy Products, H2 2013 57
Assessment by Combination Products, H2 2013 58
Assessment by Stage and Route of Administration, H2 2013 61
Assessment by Stage and Molecule Type, H2 2013 63
Cancer Pain Therapeutics - Drug Profile Updates 121
Cancer Pain Therapeutics - Discontinued Products 136
Cancer Pain Therapeutics - Dormant Products 137
Number of Products under Development for Cancer Pain, H2 2013 12
Products under Development for Cancer Pain - Comparative Analysis, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 17
Late Stage Products, H2 2013 18
Mid Clinical Stage Products, H2 2013 19
Early Clinical Stage Products, H2 2013 20
Discovery and Pre-Clinical Stage Products, H2 2013 21
Assessment by Monotherapy Products, H2 2013 57
Assessment by Combination Products, H2 2013 58
Assessment by Route of Administration, H2 2013 59
Assessment by Stage and Route of Administration, H2 2013 60
Assessment by Molecule Type, H2 2013 62
Assessment by Stage and Molecule Type, H2 2013 63